Exogenous delivery of neurotrophic factors into the cochlea of deafened animals rescues
spiral ganglion cells (SGCs) from degeneration. To be clinically relevant for human cochlear …

Hearing impairment is a major health and economic concern worldwide. Currently, the
cochlear implant (CI) is the standard of care for remediation of severe to profound hearing …

The intracochlear infusion of neurotrophic factors via a mini-osmotic pump has been shown
to prevent deafness-induced spiral ganglion neuron (SGN) degeneration; however, the use …

Sensorineural hearing loss is irreversible and is associated with the loss of spiral ganglion
neurons (SGNs) and sensory hair cells within the inner ear. Improving spiral ganglion …

Sensorineural hearing loss (SNHL) is one of the most prevalent sensory deficits in humans,
and approximately 360 million people worldwide are affected. The current treatment option …

Objectives The functionality of cochlear implants (CI) depends, among others, on the
number and excitability of surviving spiral ganglion neurons (SGN). The spatial separation …

Hearing function lost by degeneration of inner ear spiral ganglion neurons (SGNs) in the
auditory nervous system could potentially be compensated by cellular replacement using …

In the mammalian cochlea, spiral ganglion neurons (SGNs) are the primary neurons on the
auditory conduction pathway that relay sound signals from the inner ear to the brainstem …

Neurotrophins prevent spiral ganglion neuron (SGN) degeneration in animal models of
ototoxin-induced deafness and may be used in the future to improve the hearing of cochlear …

Sensorineural deafness is caused by damage of hair cells followed by degeneration of the
spiral ganglion neurons and can be moderated by cochlear implants. However, the benefit …